According to Illumina, FTC Chief Administrative Law Judge D. Michael Chappell rejected the agency’s key argument in fighting Illumina’s planned purchase of Grail: that the deal would lessen innovation in the U.S. market for multi-cancer early detection (MCED) tests like those marketed by the cancer blood test developer. The FTC had contended that Illumina is the nation’s only provider of DNA sequencing that is a viable option for MCED liquid biopsy tests . . .
See More on the Edge
Continue reading this article and more
with a GEN Edge subscription
The post StockWatch: Illumina Bounces Back After FTC Win, EU Loss appeared first on GEN – Genetic Engineering and Biotechnology News.
